Goldman Sachs maintained Pfizer, Inc. (NYSE: PFE) with a Buy rating and raises the price target from $30.00 to $32.00. Goldman Sachs commented, "PFE reported 4Q12 earnings and gave 2013 financial guidance which included highlighting efforts to optimize both the innovation-driven and value-based businesses as distinct entities.